Consistency in large pharmacogenomic studies.
作者信息
Geeleher Paul, Gamazon Eric R, Seoighe Cathal, Cox Nancy J, Huang R Stephanie
机构信息
Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA.
Division of Genetic Medicine, Vanderbilt University, Nashville, Tennessee 37232, USA.
出版信息
Nature. 2016 Nov 30;540(7631):E1-E2. doi: 10.1038/nature19838.
Abstract
摘要
相似文献
1
Consistency in large pharmacogenomic studies.大型药物基因组学研究中的一致性。
Nature. 2016 Nov 30;540(7631):E1-E2. doi: 10.1038/nature19838.
2
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.美国食品药品监督管理局批准的药品标签中的药物基因组生物标志物信息：相关药物使用情况
Pharmacotherapy. 2008 Aug;28(8):992-8. doi: 10.1592/phco.28.8.992.
3
Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.中、美、英、日四国药品说明书中药物基因组生物标志物信息的差异
J Clin Pharm Ther. 2013 Dec;38(6):468-75. doi: 10.1111/jcpt.12089. Epub 2013 Jul 29.
4
Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies.基于OWL 2 DL本体的药物基因组学知识表示、推理及基于基因组的临床决策支持
BMC Med Inform Decis Mak. 2015 Feb 22;15:12. doi: 10.1186/s12911-015-0130-1.
5
Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits.药物基因组变异比与其他二分法复杂性状相关的基因变异具有更大的效应量。
Pharmacogenomics J. 2016 Aug;16(4):388-92. doi: 10.1038/tpj.2015.47. Epub 2015 Jul 7.
6
Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.利用临床数据存储库对药物基因组学指导的药物使用进行特征分析。
Clin Pharmacol Ther. 2017 Aug;102(2):340-348. doi: 10.1002/cpt.611. Epub 2017 Jun 5.
7
Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.美国食品药品监督管理局批准的儿科药物标签中的药物基因组生物标志物信息。
Basic Clin Pharmacol Toxicol. 2015 May;116(5):438-44. doi: 10.1111/bcpt.12341. Epub 2014 Nov 21.
8
Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.药物基因组学检测能否改善重度抑郁症的临床结局？一项关于临床试验和成本效益研究的系统评价。
J Clin Psychiatry. 2017 Jun;78(6):720-729. doi: 10.4088/JCP.15r10583.
9
Systematic review of pharmacoeconomic studies of pharmacogenomic tests.系统评价药物基因组学检测的药物经济学研究。
Pharmacogenomics. 2010 Nov;11(11):1573-90. doi: 10.2217/pgs.10.145.
10
Impressions of pharmacogenomic testing among Certified Registered Nurse Anesthetists: a mixed-method study.认证注册麻醉护士对药物基因组检测的看法：一项混合方法研究。
Pharmacogenomics. 2016 Apr;17(6):593-602. doi: 10.2217/pgs.16.3. Epub 2016 Mar 29.
引用本文的文献
1
Integrated drug response prediction models pinpoint repurposed drugs with effectiveness against rhabdomyosarcoma.整合药物反应预测模型可精准找出对横纹肌肉瘤有效的重新利用药物。
PLoS One. 2024 Jan 26;19(1):e0295629. doi: 10.1371/journal.pone.0295629. eCollection 2024.
2
Machine learning-driven exploration of drug therapies for triple-negative breast cancer treatment.机器学习驱动的三阴性乳腺癌治疗药物疗法探索。
Front Mol Biosci. 2023 Aug 4;10:1215204. doi: 10.3389/fmolb.2023.1215204. eCollection 2023.
3
Ranking Breast Cancer Drugs and Biomarkers Identification Using Machine Learning and Pharmacogenomics.使用机器学习和药物基因组学对乳腺癌药物和生物标志物进行排名与鉴定
ACS Pharmacol Transl Sci. 2023 Feb 24;6(3):399-409. doi: 10.1021/acsptsci.2c00212. eCollection 2023 Mar 10.
4
Predictive validity in drug discovery: what it is, why it matters and how to improve it.药物发现中的预测有效性：是什么，为什么重要以及如何提高它。
Nat Rev Drug Discov. 2022 Dec;21(12):915-931. doi: 10.1038/s41573-022-00552-x. Epub 2022 Oct 4.
5
Computational estimation of quality and clinical relevance of cancer cell lines.计算估计癌细胞系的质量和临床相关性。
Mol Syst Biol. 2022 Jul;18(7):e11017. doi: 10.15252/msb.202211017.
6
Bipartite network models to design combination therapies in acute myeloid leukaemia.二部网络模型设计急性髓细胞白血病的联合治疗方案。
Nat Commun. 2022 Apr 19;13(1):2128. doi: 10.1038/s41467-022-29793-5.
7
Reassessing pharmacogenomic cell sensitivity with multilevel statistical models.用多层次统计模型重新评估药物基因组细胞敏感性。
Biostatistics. 2023 Oct 18;24(4):901-921. doi: 10.1093/biostatistics/kxac010.
8
Patient-Derived In Vitro and In Vivo Models of Cancer.癌症的患者来源的体外和体内模型。
Adv Exp Med Biol. 2022;1361:215-233. doi: 10.1007/978-3-030-91836-1_12.
9
Drug sensitivity prediction from cell line-based pharmacogenomics data: guidelines for developing machine learning models.从基于细胞系的药物基因组学数据预测药物敏感性：开发机器学习模型的指南。
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab294.
10
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia.贝叶斯多源回归和单核细胞相关基因表达可预测急性髓系白血病对BCL-2抑制剂的耐药性。
NPJ Precis Oncol. 2021 Jul 23;5(1):71. doi: 10.1038/s41698-021-00209-9.
本文引用的文献
1
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.利用细胞系实验和正则化回归模型预测癌症患者对多药方案的反应。
BMC Cancer. 2015 Apr 8;15:235. doi: 10.1186/s12885-015-1237-6.
2
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines.临床药物反应可以通过基线基因表达水平和细胞系中的体外药物敏感性来预测。
Genome Biol. 2014 Mar 3;15(3):R47. doi: 10.1186/gb-2014-15-3-r47.
3
Inconsistency in large pharmacogenomic studies.大型药物基因组学研究中的不一致性。
Nature. 2013 Dec 19;504(7480):389-93. doi: 10.1038/nature12831. Epub 2013 Nov 27.
4
Crizotinib for the treatment of non-small-cell lung cancer.克唑替尼治疗非小细胞肺癌。
Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261.
5
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.癌症细胞系百科全书使对抗癌药物敏感性的预测建模成为可能。
Nature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003.
6
Systematic identification of genomic markers of drug sensitivity in cancer cells.系统鉴定癌细胞药物敏感性的基因组标记物。
Nature. 2012 Mar 28;483(7391):570-5. doi: 10.1038/nature11005.
7
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).转录通路特征可预测 MEK 依赖性及对 selumetinib（AZD6244）的反应。
Cancer Res. 2010 Mar 15;70(6):2264-73. doi: 10.1158/0008-5472.CAN-09-1577. Epub 2010 Mar 9.
8
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.发现一种具有强大抗黑色素瘤活性的致癌性B-Raf激酶选择性抑制剂。
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6. doi: 10.1073/pnas.0711741105. Epub 2008 Feb 19.
9
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.使用MDM2拮抗剂Nutlin-3A治疗脂肪肉瘤的潜力。
Int J Cancer. 2007 Jul 1;121(1):199-205. doi: 10.1002/ijc.22643.
10
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.双激酶抑制剂拉帕替尼（GW572016）对HER-2过表达且经曲妥珠单抗治疗的乳腺癌细胞的活性。
Cancer Res. 2006 Feb 1;66(3):1630-9. doi: 10.1158/0008-5472.CAN-05-1182.
Zotero 插件